April 3 (Reuters) - Doctors should not automatically rule out surgery for octogenarians with early-stage lung cancer, according to a new study that challenges longstanding assumptions about age and ...
Retevmo improved event-free survival in stage 2 to 3A RET fusion-positive non-small cell lung cancer after curative therapy, per phase 3 data. Retevmo (selpercatinib) significantly improved event-free ...
SurvivorNet on MSN
A new treatment cuts the risk of early-stage lung cancer coming back by 83% — but only if doctors test for the right gene
A drug called selpercatinib cut the risk of early-stage lung cancer coming back by 83% in patients who carry a specific gene.
In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.
Lung Cancer Research Foundation Grants Team Science Award Focused on Curing EGFR-Mutant Lung Cancers
NEW YORK, April 14, 2026 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung ...
Sandra Champkins hadn’t smoked for 10 years and showed no symptoms of lung cancer when an early screening program detected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results